Seeking Alpha

Key shareholder opposes sale of Astex Pharmaceuticals

  • Activist shareholder Sarissa Capital opposes Otsuka Holdings' (OTSKF.OB) $886M bid for Astex Pharmaceuticals (ASTX), saying the $8.50-a-share offer is too low, although the U.S. biotech firm disagrees.
  • Sarissa, founded by former Carl Icahn associate Alex Denner, has also raised questions about the timing of the auction for Astex. The process came ahead of the release of key data for cancer drug SGI110, which is expected in December.
  • Sarissa is contacting potential bidders that the firm believes were left out the bidding process. Astex counters that it reached out to 33 companies but only Japan-based Otsuka made a final bid.
  • Astex letter to shareholders.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs